Molecular Stethoscope, a leading precision medicine company pioneering the next-generation cell-free mRNA (cf-mRNA) liquid biopsy, announced today that it has received an investment from the Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation (ADDF). Building on its Alzheimer's disease human proof-of-concept study (published in Science Advances), Molecular Stethoscope is now moving forward with the next phase of translational studies to develop clinical-grade products and services for the diagnosis and dynamic management of Alzheimer's disease patients and assist biopharma in the development of new therapies. In addition to its financial investment, the ADDF's expertise and network in the field of Alzheimer's disease will fuel Molecular Stethoscope's efforts in this area of neurology.